A Case of Intestinal Perforation during Bevacizumab Combination Chemotherapy for Inoperable Advanced Breast Cancer
Author:
Affiliation:
1. Department of Digestive and General Surgery, Shimane University, Faculty of Medicine
Publisher
Japan Surgical Association
Subject
General Engineering
Link
https://www.jstage.jst.go.jp/article/jjsa/77/12/77_2910/_pdf
Reference14 articles.
1. 1) Johanna M, Christine P, Henri S, et al : Intestinal perforation : an usual adverse event of bevacizumab and paclitaxel combined therapy for a metastatic breast cancer. Presse Med 2009 ; 38 : 1370-1377
2. 2) Edouard L, Lamia O, Olivier M, et al : Bevacizumab-induced small bowel perforation in a patient with breast cancer without intraabdominal metastases. Invest New Drugs 2011 ; 29 : 1500-1503
3. 3) Gray R, Bhattacharya S, Bowden C, et al : Independent review of E2100 : a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009 ; 27 : 4966-4972
4. 4) Robert NJ, Dieras V, Glaspy J, et al : RIBBON-1 : randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011 ; 29 : 1252-1260
5. 5) Brufsky AM, Hurvitz S, Peres E, et al : RIBBON-2:a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2011 ; 29 : 4286-4293
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3